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Abstract
This chapter will provide a brief overview of the fundamentals of photodynamic 
therapy with an emphasis on its use in a clinical setting. Beginning with the history 
and fundamental science underlying photodynamic therapy and delving into clini-
cal uses. There will be a primary focus on understanding the use of photodynamic 
therapy under currently approved clinical indications along with their limita-
tions. There are a number of approved therapeutic indications for photodynamic 
therapy, but there are important limitations and contraindications when applying 
this therapy. Photodynamic therapy, as applied to the clinical treatment of cancer 
will be the primary focus with further emphasis on endoluminal and specifically 
endobronchial cancer as the primary case study.
Keywords: photodynamic therapy, lung cancer, esophageal cancer, Barrett’s 
esophagus, interventional pulmonology, interventional gastroenterology
1. Introduction
Photodynamic therapy is a minimally invasive approach for the treatment of 
malignancy [1, 2]. It involves selective uptake of a photosensitizing agent, which is 
then activated by specific wavelengths of light [3, 4]. This results in oxidative dam-
age to the cells by the production of reactive oxygen species [5, 6]. This results in 
targeted cellular destruction [5, 6]. Along with this direct cellular destruction, there 
are local inflammatory effects as well as vascular thromboemboli formation, which 
allow for a further delayed therapeutic effect [5, 6]. The thromboemboli effect 
blocks blood flow to the target and thereby results in ischemia [5–7]. Photodynamic 
therapy has been approved across the world for a number of different clinical 
indications [5, 6]. This chapter will review the mechanisms and clinical utility of 
photodynamic therapy.
A photosensitizer in this context is an agent, often a porphyrin which reacts 
to light in the 500–800 nanometer range depending upon the specific agent uti-
lized [7]. The earliest described photodynamic effect was in 1900 by Raab, Von 
Tappeiner coined the term photodynamic therapy [3, 5]. Over time, hematopor-
phyrins were noted to result in tumor fluorescence [3]. This was gradually studied 
further and refined until the nature of the porphyrins was better understood. Light 
exposure following cellular uptake resulted in cellular damage and destruction [6]. 
Over time the fundamentals of this damage were better understood. Depending 
upon the exact photosensitizer, different mechanisms of damage have been pro-
posed. The major mechanisms of damage are singlet oxygen and free radical forma-
tion inducing: apoptosis, autophagy, and necrosis [6, 8, 9]. Apoptosis is a form of 
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controlled cellular death which in this case is induced when photosensitizers cause 
damage to mitochondria or the proteins of bcl-2 [6]. These are major regulators of 
the cellular death pathway. Autophagy allows for the gradual destruction of cellular 
components in an ordered manner [8]. However, necrosis is a less orderly effect and 
can often result in unintended tissue damage due to the disorganized manner of 
tissue destruction [6, 8].
Over time, many different photosensitizers have been discovered, but of these, 
only a few have seen broad clinical approval and use [5, 6, 10]. Each photosensitizer 
is reactive at a specific wavelength of light. Hematoporphyrin (HPD) was the first 
photosensitizer approved by the FDA in 1995 for the indication of esophageal 
cancer. HPD was a hematoporphyrin mixture containing monomers and chains of 
varying lengths [3, 5, 6]. Photofrin (porfimer sodium) is a refined version of HPD 
with monomers removed, and it is one of the most common clinically used agents, 
see Figure 1 [3, 5, 6]. Photosensitizers are primarily porphyrin-based and contain 
multiple ring structures [3, 5, 6, 11]. These can be applied locally or injected system-
ically, and over a period of time they will be selectively taken up by cells [3, 5, 6, 11]. 
Porfimer sodium is part of the first generation of photosensitizers developed in the 
1970s and early 1980s [5, 10, 12]. Later generations were developed as the character-
istics of the agents were chemically refined [5, 10, 12]. These later generation agents 
also tended to have decreased duration of systemic photosensitivity [3, 5, 6, 11]. 
The second generation has been refined to target longer wavelengths of light, thus 
allowing for deeper tissue penetration of the activating wavelength of light and, 
therefore greater effect [5, 6, 11]. In conjunction with the increased penetration 
of longer wavelengths of light, the light source can be embedded into the tissue to 
allow for an alternative way to increase the effect [6, 11].
Photodynamic therapy has approved indications for superficial or early-stage 
malignancies as well as late-stage malignancies [5, 6]. These indications intuitively 
make sense as light penetration is a vital component of this therapy. Given that later 
stages of malignancy typically spread systemically via blood or lymphatic spread, 
photodynamic therapy has limited utility in those cases unless it is for a local effect. 
For example, photodynamic therapy has been well described as an alternative ther-
apy in addressing central airway obstructions in lung cancer [13]. Central airway 
obstructions are typically manifestations of late-stage cancer, but photodynamic 
Figure 1. 
Comercially available porfimer sodium. Photo used with permission from Pinnacle Biologics.
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therapy can be used to clear the tumor obstructing the airway even when it does 
not have the ability to affect the entirety of the metastatic tumor burden [1, 2, 13]. 
In many ways, this focused local effect is a significant advantage over alternative 
treatments which can have greater side effects [1, 2, 13]. These cases of central 
airway obstruction can be challenging and having an option to provide a delayed 
and gradual effect that specifically targets tumor cells can be a vital therapeutic 
intervention. Skin and endoluminal malignancy treatment are approved indications 
for photodynamic therapy, but this chapter will primarily focus on endoluminal 
malignancy and especially endobronchial malignancy. Of the photosensitizing 
agents commercially available, Protomir sodium is the most well studied and widely 
available, and the best understood.
Photodynamic therapy usage in lung cancer is used as the primary example 
for a few reasons. The primary being that in many ways. it is the most challenging 
application. The esophagus consists of a single cylindrical region where the therapy 
is applied, and blockage of it is not life threatening. Utilization of photodynamic 
therapy on the skin similarly has limited side effects. However, utilization of photo-
dynamic therapy within the pulmonarysystem is limited to only some surfaces, and 
damage to this tissue has the potential for life threatening complications. Therefore, 
understanding the practical applications of photodynamic therapy within the 
context of lung cancer can be extrapolated to other vital organs.
2. Contraindications of photodynamic therapy
Photodynamic therapy and porfimer sodium, in particular, has a set of contra-
indications that are worth noting. Porfimer sodium and really any photodynamic 
therapy cannot be used therapeutically in individuals with porphyria [14, 15]. These 
individuals have one of a group of diseases that allow for an increased accumulation 
of porphyrins utilized by the human body in hemoglobin production, and these 
porphyrins increase photosensitivity [16]. Given the foundation of photodynamic 
therapy is localized photosensitivity by means of porphyrins, this contraindication 
is reasonable [3]. Other contraindications are existing tracheoesophageal/broncho-
esophageal fistulas [17]. These are abnormal connections between the airway and 
the esophagus. Tumor eroding into the airway are also contraindicated given the 
risks that will be described below [17]. Additionally, given the delayed time scale 
of photodynamic therapy, usage in emergency situations when therapy must be 
delivered immediately would not be optimal [17].
3. Fundamentals of lung cancer
Throughout the world, lung cancer is one of the most prevalent cancers 
 worldwide; it is the most commonly occurring cancer in men and the third most 
common in women [18]. The best treatment responses to lung cancer are early 
detection, diagnosis, and treatment [18, 19]. Photodynamic therapy has a robust 
role in both early and late-stage lung cancers [20]. Lung cancer has significant mor-
bidity and mortality, and there has been strong interest and research in identifying 
treatments to improve the morbidity and mortality associated with this disease 
process [18, 19, 21]. Frequently, management of lung cancer is discussed in local 
meetings at tumor boards allow physicians of different specialties to determine the 
optimal next stage of diagnosis or treatment [21]. Knowing the risks and benefits of 
photodynamic therapy in this context can allow for discussion of the optimal role it 
can play in treatment.
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4. Fundamentals of photodynamic therapy for lung cancer
In the United States, the FDA has approved the usage of photodynamic therapy 
(porfimer sodium) for endobronchial malignancy [17]. Within the airway, this 
treatment is applied to non-small cell lung cancer that is not otherwise treatable by 
surgery or radiation therapy [17]. Beyond this, the limitation to therapy is solely the 
ability to illuminate the desired areas of disease with the correct wavelength of light 
[3, 6, 11, 22]. This, therefore limits therapy to lesions that are primarily visible on 
bronchoscopy. Standard bronchoscopy is able to visualize airways out to the fourth 
or fifth generation of airways [23]. The airways of the human go out past twenty 
generations which can limit utility to only the larger central airways [24]. There 
have been preliminary studies utilizing electromagnetic navigational bronchoscopic 
approaches to treat more distal malignancies, but these are still early studies [25]. 
There are also tools now available, including robotic bronchoscopic platforms that 
allow for navigation, direct visualization, and intervention down to the ninth gen-
eration of airways [26]. Although not directly studied with photodynamic therapy, 
these recent developments could greatly expand the role of photodynamic therapy 
in lung cancer.
Currently, the major roles for photodynamic therapy in lung cancer are utilizing 
it early-stage carcinoma in situ or in central airway lesions [1, 2, 13, 20, 27]. There 
have been multiple off-label uses and case series reporting success in other disease 
processes, such as in tracheal papillomatosis [28]. This is a relatively benign but 
recurrent papillomatosis disease of the trachea causing partial obstruction overtime 
with significant risk for malignant transformation of the underlying papillomas 
[28]. Although not directly approved for this indication, as will be discussed, 
endoluminal obstruction in an early or premalignant disease process is not too far 
from the currently approved indications [28].
Photodynamic therapy can also target the vasculature that feeds areas of malig-
nancy [5]. This can require illumination with the appropriate wavelength of light up 
to 30 minutes after exposure/injection to the photosensitizer [5, 7]. This ensures the 
photosensitizers are still circulating and in the vasculature near the target malignant 
cells [5, 7]. This approach is more often used in ocular conditions such as macular 
degeneration to target neovascularization as well as cutaneous lesions of the skin 
[5]. Photodynamic therapy targeting vasculature has demonstrated efficacy in ani-
mal models of solid tumors [7]. However, additional studies need to be performed.
There has been increasing interest in the local injection of photosensitizers 
directly into tumors [5, 12]. Although only early studies have been done, this has 
demonstrated efficacy in tumors as small as 8 mm in diameter [12]. However, again 
these are results from early studies. In general, there are many areas of research 
both clinical and in basic science for photodynamic therapy. However, clinical 
utilization often has stringent criteria [17]. Therefore, the focus on the currently 
approved indications will be to better understand where growth in clinical utiliza-
tion of this technique will need to occur. Given the requirements for safely deliver-
ing therapy to patients, understanding these limitations can help guide the future 
direction of clinical and translational research. Lung cancer will be utilized as a 
primary model given the unique characteristics of its prevalence and complexity, 
and esophageal cancer use will be contrasted to it.
5. Approach to photodynamic therapy in lung cancer
Airway lesions must first be identified then confirmed bronchoscopically to 
ensure the lesions can be reached and light can be applied to the desired areas. 
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Additionally, it is important to note the anatomy of the area surrounding the 
lesions. If the lesion location is adjacent to the large blood vessels surrounding the 
airway, the risk of massive hemoptysis should be considered prior to administer-
ing therapy [29]. This is also true for large central airway tumors that may have 
large vascular beds [29, 30]. As necrosis occurs, these perforating vessels can 
potentially lead to significant bleeding. The risk of further airway compromise in 
an already partially compromised airway (i.e. from the central airway tumor) is 
already significant in these scenarios. This is a greater consideration when there 
is malignancy both intrinsic and extrinsic to the airway. Additionally, there is a 
risk of fistula formation into the surrounding structures of the thorax such as: the 
esophagus, mediastinum, or blood vessels (pulmonary artery, superior vena cava, 
innominate vein, etc.) [31]. It should also be noted that mediastinal anatomy, 
especially airways and blood vessels will shift out of their traditional anatomic 
locations in the presence of large tumor burden. Being aware of these changes 
can be vital when reviewing a patient for consideration of photodynamic therapy. 
Depending upon the shape and course of the lesions, consideration should be 
given to the anticipated inflammatory effects during photodynamic therapy as the 
process of controlled and uncontrolled cell death occurs. The areas particularly at 
risk are the trachea, carina, and main stem bronchi [17, 29]. In these cases, long or 
circumferential tumors would be at a higher risk of obstructing the airway given 
the expansion associated with edema that would be anticipated with photody-
namic therapy [17]. Additionally, individuals with impaired liver and/or renal 
function can have delayed clearance of porfimer sodium [17]. This delayed clear-
ance can prolong the period of photosensitivity beyond 90 days when it would 
typically be ~30 days [5, 12, 28].
Skin/systemic photosensitivity is the most significant and common adverse 
effect associated with photodynamic therapy [17]. Following the injection of the 
photosensitizer, it is important to ensure that patients are able to protect their skin 
until the photosensitizer is fully cleared [17]. This can be as short as two weeks and 
sometimes as long as three months [5, 6, 12]. Ensuring patients remain indoors for 
this period to prevent serious collateral skin damage from occurring is vital to safely 
administering this therapy [17]. Porfimer sodium has not been extensively studied 
in pregnant and lactating women, but there are animal studies that have demon-
strated adverse effects [17]. This has led to porfimer sulfate having an FDA preg-
nancy category of C, ie animal studies demonstrating adverse fetus effects without 
any well-controlled human studies, but the benefits may warrant consideration in 
this population. Similarly, there are no studies on lactation either, so it is not known 
if porfimer sulfate is secreted in breast milk [17].
Porfimer sodium is injected systemically at a dosage of 2 mg/kg intravenously 
over 3–5 minutes; this is considered time zero [2, 28]. From this point onwards, 
the patient will be extremely photosensitive and must wear protective clothing. 
Additionally, there can be ocular sensitivity, so it is important for patients to wear 
dark glasses that transmit <4% of white light over the next 30 days [17]. Over the 
next 2–3 days from time zero, the porfimer sodium will preferentially localize to the 
desired areas of malignancy over this period of time [5, 6]. Next, the patient will 
be brought in for a bronchoscopy for the second stage of the treatment [17]. This 
typically will occur 40–50 hours from time zero [1, 2]. Upon reidentification of the 
lesions of interest, here a laser light diffuser illuminating at a wavelength of 620 nm 
with 200 J/cm for the length of the diffuser is utilized, Figure 2 shows available 
diffusers [17]. The duration of illumination is eight minutes and twenty seconds 
(five hundred seconds) [17]. If the tissue of the lesion is soft and allows, the fiber 
can be positioned interstitially, otherwise the fiber remains within the lumen of 
the airway for the five hundred seconds of illumination [17]. During this period all 
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individuals, including the patient receiving therapy, in the procedure room wear eye 
protection. Following endoillumination of the desired lesions, it is often advisable 
to have the patients hospitalized for observation [17]. As the tumor sloughs off, 
it can often be necessary to debride the necrotic tissue to prevent obstruction of 
the airway [17]. This is recommended to be done 48–72 hours after the light treat-
ment, or 88–122 hours from time zero [17]. If it is clinically indicated a second light 
treatment can be performed 96–120 hours from time zero [17]. Given there is an 
overlap between when tissue debridement is performed and when a second light 
therapy can be indicated, they are sometimes performed simultaneously. Although 
the tumor debridement is recommended to be 48–72 hours from light therapy, 
there can often be a very robust tissue response, and the debridement may need to 
be done sooner and multiple times before the photodynamic effect is fully realized. 
Given that airway obstruction can be an emergent and life-threatening condition if 
not intervened upon quickly, there is a strong reason to keep patients hospitalized 
for the duration of this therapy.
Following the first injection of Porfimer sodium, subsequent injections and light 
exposures can be repeated as described above up to three times [17]. However, each 
treatment must be separated by thirty days. If radiation therapy was performed at 
any point there should be a period of approximately four weeks from the comple-
tion of radiation before photodynamic therapy is attempted [17]. After exposure 
to porfimer sodium, exposure to sunlight can cause a significant skin reaction, but 
indoor light can help clear the residual photosensitizer [17]. The duration of the of 
photosensitivity period can vary from patient to patient, and should be individual-
ized, but a minimum of thirty days should be considered [17]. To determine if there 
is any residual photosensitivity, patients can be instructed to expose an area of skin 
to sunlight for approximately ten minutes and then observe for any skin reaction 
over the subsequent twenty-four hours. As it may be difficult to remember exactly 
where the exposure was, using a pen or marker to outline the sun-exposed area 
can help identify this area. Following treatment, chest discomfort secondary to the 
associated inflammatory effect may require temporary analgesia until the inflam-
mation subsides [17].
Figure 2. 
Comercially available laser diffuser fibers for endobronchial use. Photo used with permission from Pinnacle 
Biologics.
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6. Esophageal cancer and high-grade Barrett’s esophagus
Similar to lung cancer, the dosing for porfimer sodium is 2 mg/kg [17]. The laser 
light diffuser utilized however, is different. In esophageal cancer a laser light diffuse 
of 200 J/cm is utilized, and in Barrett’s esophagus, a laser light diffuser of 130 J/
cm is used, see Figure 2 for current available laser light diffusers [17]. High-grade 
Barrett esophagus is the final precancerous stage before progressing to esophageal 
cancer [32]. Typically, high- grade Barrett esophagus is treated by surgical resec-
tion [32]. Treatment of high-grade Barrett’s esophagus is an approved indication 
for photodynamic therapy if surgical resection is not an option [17, 33]. Treatment 
of esophageal cancer is an approved treatment for photodynamic therapy if there 
is complete obstruction of the esophagus by tumor or a partial obstruction that 
cannot adequately be treated by laser therapy/debridement [17, 33]. Given that the 
esophagus travels just posterior to the trachea and mainstem bronchi, the risks 
of fistula formation are the same and primarily to the trachea, blood vessels, and 
mediastinum. Specifically, if a tumor has already spread into these structures, 
there is a higher risk of fistula formation as the malignant cells are destroyed from 
photodynamic therapy. Esophageal varices are veins within the esophagus that 
are enlarged. These veins are at high risk for bleeding and rupture at baseline, and 
photoactivation of the photosensitizer in these veins could lead to significant bleed-
ing [17]. Specifically, if these varices are >1 cm in diameter, the risk is likely too 
great [17]. Following treatment of Barrett esophagus, there is a risk of esophageal 
strictures resulting in food dysphagia (inability to swallow) [34]. In research studies 
these strictures occurred in 38% of subjects within six months of initiating photo-
dynamic therapy. This is typically treated with dilation of the stricture, but it may 
require other treatments, depending upon the severity [17].
In esophageal cancer the timeline from injection to photoactivation of the 
photosensitizer is the same as in lung cancer. The time of injection (time zero) to 
photoactivation (40–50 hours from time zero) to potential second photoactivation 
(96–120 hours) is the same [17]. However, the duration of the treatment is differ-
ent, the exposure to light is 12.5 minutes (750 seconds) [17]. A minimum of 30 days 
between injections of porfimer sodium is recommended with similar distancing 
between radiation therapy and photodynamic therapy [17]. Additionally, just as 
in lung cancer, endoscopic re-evaluation between treatments is recommended to 
ensure no complications have occurred such as fistula formation [17]. Barrett’s 
esophagus has similar injection to photoactivation of the photosensitizer is the same 
as in lung cancer and esophageal cancer [17]. The time of injection (time zero) to 
photoactivation (40–50 hours from time zero) is the same [17]. The duration of 
treatment with light can however vary depending upon the length of the laser light 
diffuser utilized to deliver therapy with a maximum length of 7 cm treated at any 
one time [17]. In high-grade Barrett’s esophagus, the time interval between injec-
tions of porfimer sodium is a minimum of 90 days [17].
7. Building a photodynamic therapy program
In building a program that utilizes photodynamic therapy, a collaborative and 
team-based approach is often vital. This is especially true in cases immediately 
after light exposure when interventions may need to be done at any hour of the day 
depending upon the reaction to photdynamic therapy. In the world of Oncology, 
there are frequent meetings amongst local specialists to discuss how best to diag-
nose and treat suspected cancers. These tumor boards meet regularly to review 
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patient cases and determine next steps [21]. Given that photodynamic therapy uses 
similar equipment, it is reasonable to share equipment across a single institution to 
maximize utility. Depending upon the country/locale it is administered cost of the 
drug, approval by insurance/regulatory agencies, and equipment costs can easily 
add up significantly. Porfimer sodium is sold commercially as Photofirin and is 
sold by Concordia Healthcare Corporation. Its retail cost in the United States is > 
$20,000 per dose. Between the cost of the drug, facility fees, physician fees, and the 
need for frequent short term follow up the upfront costs may be high. The upfront 
costs of utilizing this therapy can be difficult to overcome, but a shared resource 
model can help overcome this given the benefits provided. With a robust clinical 
program, there is always room to expand the research aspect of photodynamic 
therapy, whether it is basic research, translational research, or clinical research.
8. Conclusion
In the years since photodynamic therapy was first discovered and developed 
through today, it has gone through numerous iterations. From the early identifica-
tion of fluorescence to the discovery of selective uptake and tissue destruction 
with light exposure, the field of photodynamic therapy has had great potential. 
The number of publications has increased year over year, and there are no signs of 
this decreasing in the near future. From a biochemical perspective, its mechanism 
of action is unique and it shows great promise for the future as a scientific tool as 
well as a therapeutic one. However, as a therapeutic instrument there are currently 
limited indications, and even amongst these indications there are both obvious and 
subtle advantages and disadvantages in its use. Fully understanding the limitations 
of the current clinical role of photodynamic therapy can allow for future research 
and development to better address the current shortcomings and allow for even 
more widespread use of this technology.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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